A-71623 TFA
Names
Biological Activity
[Description]:
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC50s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively[1].
[Related Catalog]:
[Target]
IC50: 3.7 nM (CCKA receptor in radioligand binding assays)[1]
[In Vitro]
In guinea pig gastric glands, the affinities of A-71623 for the cholecystokinin (CCK)-B/gastrin receptor were 11 μM[1].
[In Vivo]
A71623 (A-63387; i.c.v., but not i.p., injections) reduces food intakes and suppresses intakes of a liquid diet in both deprived and sated rats[2]. A71623 dampens Purkinje neuron pathology and associates deficits in motor performance in Pcp2-ATXN1[30Q]D776;Cck-/- and Pcp2-AXTN1[82Q] mice[3]. A71623 improves motor performance of Pcp2-ATXN2[127Q] SCA2 mice[3]. Animal Model: Adult male, Sprague-Dawley rats[2] Dosage: 5 μL Administration: Intracerebroventricular (i.c.v) administration, A-71623 was infused using a 28 gauge injection cannula in a volume of 5uL over 60 s Result: Reduced food intakes and suppressed intakes of a liquid diet. Animal Model: ATXN1[30Q]-D776, ATXN1[82Q]-D776, ATXN2[127Q], and WT/FVB/NJ mice [3] Dosage: 0.02 mg/kg/day Administration: Osmotic minipumps containing either A71623 (0.02mg/kg/day) were implanted intraperitoneally (i.p.) Result: Treatment dampened Purkinje neuron pathology in ATXN1[30Q]D776;Cck-/- mice and ATXN1[82Q] mice. Improved motor performance in ATXN2[127Q] mice.
[References]
Chemical & Physical Properties
[ Molecular Formula ]:
C44H56N8O9
[ Molecular Weight ]:
840.96
[ Exact Mass ]:
840.41700
[ PSA ]:
254.15000
[ LogP ]:
6.24030
[ Storage condition ]:
-20°C